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ABSTRACT
We evaluated the antitumor activity of tandem cycles of high-dose chemotherapy with autologous peripheral
stem cell transplantation (aPSCT) in relapsed germ cell tumors by using high-dose paclitaxel, carboplatin,
etoposide, and ifosfamide. Thirty-three patients were entered, and 31 underwent protocol therapy. Paclitaxel
350 mg/m2 (5 patients) or 425 mg/m2 (26 patients) by 24-hour continuous intravenous infusion was followed
by 3 daily doses of carboplatin and either etoposide (cycle 1) or ifosfamide/mesna (cycle 2). The carboplatin
dose had a calculated area under the curve of 7 mg-min/mL, and the daily dose of etoposide was 20 mg/kg
(cycle 1). Ifosfamide 3 g/m2/d for 3 days (with mesna uroprotection) was substituted for etoposide in cycle 2.
Each cycle was supported by granulocyte colony-stimulating factor–mobilized peripheral blood stem cells.
Thirty-one patients were evaluable for response, toxicity, and long-term disease control. Two patients did not
undergo aPSCT because of rapid disease progression. Nineteen patients received both cycles of aPSCT, 8
progressed after cycle 1, 3 refused the second cycle, and 1 died of fungal infection during cycle 1. Twelve
patients remain relapse free at a median of 67 months from the initiation of therapy. Whereas the International
Germ Cell Cancer Collaborative Group category at the time of initial diagnosis did not seem to predict
outcome, the patient’s probability of achieving durable remission was significantly associated with the Beyer
prognostic score at the time of protocol entry. Regimens containing the most active agents in relapsed
nonseminomatous germ cell tumors, including high-dose paclitaxel, are well tolerated and have promising
activity even in patients with poor-risk features who do not achieve durable remissions with standard therapy.
The Beyer prognostic system is a valuable predictor for patients undergoing aPSCT.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
The treatment of advanced germ cell tumors
GCTs) with cisplatin-based combination chemother-
py with or without surgery results in a cure for 70%
o 80% of unselected patients. Approximately half of
he patients who do not achieve remission with ﬁrst-
ine therapy have a complete marker response to sec-
nd-line therapy at standard doses; however, less than
alf of these patients are cured [1]. Although autolo-
ous peripheral stem cell transplantation (aPSCT) is C
B&MTrequently used in the United States for patients in
rst or subsequent relapse [2,3], the precise indica-
ions for this modality remain ill deﬁned. Important
nanswered questions include identiﬁcation of the
ost active agents, the selection of patients most likely
o beneﬁt from aPSCT, and the potential superiority
f tandem cycles over single cycles of high-dose che-
otherapy.
The prognostic system developed by the Interna-
ional Germ Cell Cancer Collaborative Group (IGC-
CG) [4] provides important information regarding
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9nitial characteristics that have been widely accepted
nd applied in the design of phase II and III trials for
nitial therapy of GCT. To date, a comparable system
or patients in relapse or with an incomplete response
o initial chemotherapy has not been routinely ap-
lied. A series of phase II studies in the United States
ave led to the widespread use of tandem cycles of
igh-dose carboplatin and etoposide with or without
yclophosphamide or ifosfamide (see review [3]), but
his approach has not yet been evaluated in a phase III
andomized trial for patients with refractory or re-
apsed GCT. It is common in the United States to
reat patients in a “favorable” relapse (low-volume,
ow-marker disease after a complete response to ﬁrst-line
hemotherapy) with second-line therapy consisting of
tandard doses of cisplatin-based chemotherapy, whereas
atients with less favorable characteristics or subsequent
elapse are more often referred for aPSCT, by which
ime the durable remission rate from tandem aPSCT
s only 20% to 40% [3].
Because GCT is typically a disease of young pa-
ients with favorable organ function, an important
onsideration is to develop regimens that incorporate
ewer agents with proven activity that have acceptable
afety and toxicity proﬁles. On the basis of a series of
ecent studies documenting the activity of paclitaxel as
single agent [5] in GCT and our own studies and
hose of others regarding dose escalation of paclitaxel
n aPSCT [6-8], we designed a regimen of tandem
ycles of aPSCT that incorporated the 2 most active
lasses of agent (paclitaxel and carboplatin) while still
ncluding etoposide, ifosfamide, and carboplatin, as we
reviously evaluated in patients with advanced GCT
9]. Because we proposed to administer tandem cycles
f aPSCT, each containing high-dose paclitaxel, we
sed data from our own experience and others’ expe-
iences regarding the dose-limiting toxicity of pacli-
axel with aPSCT; this toxicity consists of peripheral
europathy at the maximum tolerated dose of 775
g/m2 administered as a 24-hour continuous intrave-
ous (IV) infusion after doxorubicin and high-dose
yclophosphamide [7] or in combination with high-
ose cisplatin and high-dose cyclophosphamide [8].
hen we combined escalating doses of paclitaxel with
igh-dose ifosfamide, carboplatin, and etoposide,
ose-limiting stomatitis and diarrhea were observed at
paclitaxel dose of 275 mg/m2 over 24 hours. When
toposide was omitted from the regimen, the pacli-
axel could be escalated to a maximum dose of 575
g/m2 over 24 hours, and the dose-limiting toxicity
as neuropathy [8].
With these considerations about the safety of
igh-dose paclitaxel and our intent to use the drug in
ombination with carboplatin (both cycles) and eto-
oside (1 cycle), we incorporated an abbreviated dose
scalation of paclitaxel for both cycles. The starting
ose of paclitaxel for each cycle was 350 mg/m2, and 2 i
04dditional dose levels, 425 and 500 mg/m2, were
lanned, with 5 patients in each cohort to be observed
hrough the ﬁrst cycle before dose escalation in the
ext cohort of patients. The rationale for administer-
ng tandem cycles of high-dose therapy was a general
rinciple of chemotherapy: a single cycle would be
nadequate to provide optimal cell kill. The speciﬁc
ustiﬁcations for tandem cycles of the regimen we
tudied were an effort to avoid the severe neurotoxic-
ty related to a single high dose of paclitaxel [10] and
desire to combine the paclitaxel and carboplatin
backbone” with a different third drug in each cycle
etoposide in cycle 1 and ifosfamide in cycle 2).
ATIENTS AND METHODS
atients
To be eligible for the trial, patients older than the
ge of 15 years with a Karnofsky performance status
70% were required to have biopsy-proven, measur-
ble (by radiographic study or serum tumor marker
levation), and relapsed or refractory GCT judged to
e incurable by standard salvage therapy; patients in
elapse who had intermediate- or high-risk disease at
nitial diagnosis [4] were included. Because of their
articularly unfavorable prognosis, patients with me-
iastinal primary GCT in ﬁrst relapse and those pa-
ients who had received prior paclitaxel (maximum
umulative exposure of 600 mg/m2) as third-line
reatment were required to be responsive to salvage
herapy. Patients with a history of central nervous
ystem metastases were required to have completed
herapy with surgery, radiation, or both and to be
eurologically stable off of corticosteroids before pro-
ocol enrollment.
There was no limit on prior cisplatin; peripheral
europathy was not considered an exclusion criterion.
atients were required to have a calculated creatinine
learance of 70 mL/min before cycle 1 and 60
L/min before cycle 2. Before stem cell collections
nd each cycle of aPSCT, serum bilirubin had to be
1.6 mg/dL, and aspartate aminotransferase and ala-
ine aminotransferase had to be 2 times the institu-
ional upper limit of normal. Patients with positive
erology for hepatitis B or C were to undergo liver
iopsy to rule out chronic active hepatitis or cirrhosis;
atients with positive human immunodeﬁciency virus
erology were excluded. Before beginning granulocyte
olony-stimulating factor (G-CSF)–mobilized periph-
ral stem cell collections and before each treatment
ycle, patients were required to have an absolute neu-
rophil count 1500/L, platelets 120 000/L, and
emoglobin10 g/dL. Patients were required to have
normal radionuclide-determined left ventricular
jection fraction and no evidence of arrhythmias or
schemia on electrocardiogram. Requirements for pul-
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Bonary function included a room air arterial oxygen
oncentration 70 mm Hg, a forced expiratory vol-
me in 1 second of 2.0 L or 75% of the predicted
ower limit of normal, and no history of bleomycin-
nduced pulmonary toxicity. All patients provided
heir voluntary, written informed consent after proto-
ol approval by the institutional review board, in ac-
ordance with an assurance ﬁled with and approved by
he Department of Health and Human Services.
reatment Protocol
Stem cell mobilization. All patients received G-CSF
0 g/kg/d subcutaneously for 4 days before the ini-
iation of leukapheresis, followed by daily G-CSF dur-
ng collections until the total collected product ex-
eeded 4  106 CD34 cells per kilogram. G-CSF
as withheld if the total white blood count was
80 000/L.
Chemotherapy regimens. Cycle 1 chemotherapy
onsisted of paclitaxel, etoposide, and carboplatin.
remedication for paclitaxel consisted of 2 doses of
examethasone 20 mg orally given at 12 and 6 hours
efore the initiation of paclitaxel, which was given as a
4 hour continuous IV infusion at 350 mg/m2 (ﬁrst 5
atients) or 425 mg/m2 (all other patients) on day 7.
mmediately before the infusion, patients also re-
eived diphenhydramine 50 mg orally and cimetidine
00 mg orally. On days 6, 5, and 4, each patient
eceived etoposide 20 mg/kg IV over 2 hours and
arboplatin at a calculated area under the curve [11] of
mg-min/mL IV over 30 minutes. Premedication for
toposide consisted of hydrocortisone 50 mg IV and
iphenhydramine 50 mg IV, which were repeated
alfway through the etoposide infusion. Premedica-
ion for carboplatin included dexamethasone, loraz-
pam, and a 5-hydroxytryptamine-3 antiemetic agent.
Patients with increasing serum tumor markers or
ther clinical or radiographic evidence of tumor pro-
ression before cycle 2 were taken off protocol ther-
py. Otherwise, all patients who had recovered from
he acute toxicities associated with cycle 1 were per-
itted to begin cycle 2 at 2 to 4 weeks after hospital
ischarge. All of the pretreatment tests detailed pre-
iously were required before cycle 2, with the excep-
ion of brain magnetic resonance imaging, viral sero-
ogic tests, and cardiac and pulmonary function
esting.
Cycle 2 chemotherapy consisted of paclitaxel, if-
sfamide, and carboplatin. Paclitaxel and carboplatin
ere administered exactly as in cycle 1. Ifosfamide 3
/m2 was given daily IV over 30 minutes on days 6,
5, and 4. Allopurinol 300 mg orally was adminis-
ered daily on day 7 through day 0, and alkaline
ydration and diuresis were established before ifos-
amide and continued throughout its administration.
esna was given as an initial 1 g/m2 IV bolus imme- m
B&MTiately before the ﬁrst dose of ifosfamide, followed by
10 g/m2 continuous IV infusion over 72 hours (24
ours beyond the ﬁnal ifosfamide dose). All patients
ad a urinalysis daily on days 6 through 3. If the
atient developed hematuria (50 red blood cells per
igh-power ﬁeld), ifosfamide was to be withheld,
esna was to be continued, and additional hydration
as to be provided; ifosfamide was to be resumed
pon the resolution of hematuria.
Stem cell reinfusion and supportive care. Cell infu-
ions and protocol-speciﬁc supportive care were iden-
ical for the 2 cycles. Because we had previously dem-
nstrated earlier granulocyte recovery by splitting the
nfusion of autologous peripheral stem cells [12], all
atients received 12.5% of the total CD34 stem cell
roduct on day 2 of each cycle and 37.5% of the
roduct on day 0 of each cycle. Premedication for
ach stem cell infusion consisted of diphenhydramine
0 mg IV and acetaminophen 650 or 1000 mg orally.
ontinuous oximetry and frequent vital sign measure-
ents were required during and for at least 4 hours
fter each infusion, and symptom management con-
isted of meperidine for chills and oxygen for hypoxia
r dyspnea in association with the cell infusions. All
atients received G-CSF 5 g/kg/d IV starting on day
2 and continuing until the absolute neutrophil count
xceeded 1000/L for 3 consecutive days. Platelet
ransfusion support was provided to keep the platelet
ount 20 000/L, and red blood cell transfusions
ere provided to keep the hemoglobin 9 g/dL. An-
imicrobial prophylaxis consisted of levoﬂoxacin 500
g/d orally or IV and amphotericin B 10 mg/d IV.
atients who became febrile were treated with addi-
ional broad-spectrum antibiotics, and antimicrobial
gents were adjusted as indicated by the clinical con-
ition and culture results. All patients with positive
erpes simplex serology received acyclovir 250 mg/m2
ntravenously every 8 hours during the period of neu-
ropenia and until the resolution of stomatitis. Pa-
ients were treated in single rooms equipped with
ositive-pressure air ﬂow during the period of neutro-
enia.
Clinical and data monitoring. From the initiation of
hemotherapy until recovery of blood counts and ad-
quate oral intake, all patients had daily laboratory
esting consisting of a complete blood cell count (with
differential white blood cell count when the total
hite blood cell count was 500/L) and a serum
hemistry panel that included electrolytes, blood urea
itrogen, creatinine, and glucose. A comprehensive
erum chemistry panel including hepatic transami-
ases, bilirubin, alkaline phosphatase, lactate dehydro-
enase, uric acid, albumin, calcium, phosphorus, and
agnesium was performed at least 3 times weekly, and
oagulation studies were performed twice weekly. Se-
um tumor markers (alfa fetoprotein [AFP] and -hu-
an chorionic gonadotropin [HCG]) were measured
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9eekly, starting at the time of protocol enrollment. A
hest radiograph was performed at least weekly. After
ecovery from cycle 2, patients whose serum tumor
arkers had normalized and who had residual masses
ere referred for surgical resection.
The National Cancer Institute Common Toxicity
riteria, version 2.0 (http://ctep.info.nih.gov/reporting/
tc-3test.html), were used to assess toxicities. Patients
ere evaluated as often as necessary to conﬁrm recov-
ry from acute toxicities and then underwent clinical
nd laboratory evaluation at monthly intervals for the
rst year. Evaluations were performed every 2 months
uring the second year, every 4 months during the
hird year, twice during the fourth year, and then
early. Radiographic evaluations for tumor assessment
ere required with every second clinical evaluation
ntil 5 years after treatment and then at the discretion
f the physician.
tatistical Methods
Overall survival and progression-free survival,
ased on intention to treat, were calculated from the
nitiation of protocol procedures (G-CSF mobiliza-
ion before stem cell collection) to the time of death
rom any cause or tumor marker progression. Stan-
ard Kaplan-Meier methods were used for survival
nalysis by using S-Plus software (S-Plus 6.0; Insight-
ul, Seattle, WA). All signiﬁcance testing was 2 sided
log-rank test).
ESULTS
atient Characteristics and Treatment Details
Thirty-three patients were initially enrolled and
et the eligibility criteria before protocol procedures
ere initiated. Two of these patients had rapidly pro-
ressive disease, and 1 also had poor stem cell mobi-
ization that precluded protocol therapy. The patient
haracteristics are listed in Table 1. Patients included
2 men and 1 woman, with a median age of 30 years
range, 17-49 years). Twenty-four patients were clas-
iﬁed as having had poor-risk GCT at initial diagno-
is, on the basis of 1 or more of the criteria established
y the IGCCCG [4]. The criteria by which these
atients fell into the poor-risk category included lac-
ate dehydrogenase 10 times the institutional upper
imit of normal (1 patient; initial values were not
vailable in 6 patients), metastatic disease in 1 or more
isceral (brain, bone, or liver) sites (all 24 patients),
ediastinal-primary nonseminomatous GCT (3 pa-
ients), serum -HCG 50 000 U/L (8 patients), and
FP 10 000 ng/mL (7 patients). The median dura-
ion of response to ﬁrst-line therapy was 4 months
range, 0-128 months). Twelve patients had normal-
zed serum tumor markers in response to salvage ther-
py, and 21 had increasing markers. Two patients had p
06esponded to paclitaxel-containing salvage therapy.
he tumor histologic results were choriocarcinoma (n
8), embryonal carcinoma/teratocarcinoma (includ-
ng yolk sac and endodermal sinus and including the 1
emale patient; n  18), mediastinal germ cell syn-
rome with poorly differentiated carcinoma (n  1),
ixed GCT (n 1), and pure seminoma (n 5). The
umbers of prior treatment regimens were 1 (3 pa-
ients), 2 (27 patients), or 3 (3 patients). Eleven pa-
ients had prognostic scores of 2 by the system of
eyer et al., and 22 patients had scores 2 by these
riteria [13].
Two patients did not proceed to aPSCT because
hey had rapidly progressive disease. Twelve patients
eceived only the ﬁrst cycle of aPSCT, for the follow-
ng reasons: 8 had progressive GCT after cycle 1, 3
efused a second cycle (2 patients developed severe
eripheral neuropathy, and 1, with a history of su-
raventricular tachycardia, developed a symptomatic
pisode during the ﬁrst cycle), and 1, a heavy smoker,
ied during cycle 1 as a result of fungal pneumonia.
ineteen patients completed both cycles of protocol
herapy. The median interval between day 1 of cycle 1
nd day 1 of cycle 2 was 58 days (range, 41-155 days),
nd the median interval between hospital discharge
fter cycle 1 and admission for cycle 2 was 32 days
range, 12-134 days).
oxicities of aPSCT
The grade 3 and 4 toxicities of therapy for the 31
able 1. Patient Characteristics
Variable Data
isease
Poor risk at diagnosis, in first relapse 24
-HCG >50 000 U/L 8
AFP >10 000 ng/mL 7
LDH >10 times upper limit of normal 1 (unknown in 6)
Mediastinal primary tumor 3
Visceral metastasis 22
Histologic characteristics
Choriocarcinoma 8
Embryonal/yolk sac 17 male, 1 female
Mixed nonseminometous GCT 1
Pure seminoma 5
Mediastinal germ cell syndrome with
poorly differentiated carcinoma 1
emographics
Male/female 32/1
Age range, y (median) 17–49 (30)
o. of prior regimens
1 3
2 27
3 3
esponse status immediately before
protocol therapy
Responsive disease (markers normal) 12
Progressive disease (markers increasing) 21
DH indicates lactate dehydrogenase.atients who began the aPSCT regimen are listed in
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Bable 2. Severe stomatitis was predominantly limited
o cycle 1 at the paclitaxel dose of 425 mg/m2. One of
patients at the lower paclitaxel dose of 350 mg/m2
nd 5 of 19 patients who underwent the second cycle
f aPSCT experienced grade 3 or 4 stomatitis. Be-
ause dose-limiting mucositis occurred in the ﬁrst
ycle at the second dose level of paclitaxel (425 mg/
2), we did not further escalate the paclitaxel dose
uring the ﬁrst cycle. Although the mucositis in the
econd cycle of therapy was only mild and was not
ose limiting, we elected not to escalate the paclitaxel
ose in that cycle because of the concern that patients
ight develop irreversible cumulative neurotoxicity.
ther gastrointestinal toxicities were similar in both
ycles. All patients developed a subacute sensory neuro-
able 2. Grade 3/4 Acute Regimen-Related Toxicities of Protocol
herapy*
Variable
Cycle 1
(n  31)†
Cycle 2
(n  19)‡
tomatitis 21 6
ausea/vomiting 9 3
epatic
Bilirubin alone 3 2
Bilirubin and transaminase 1 1
Transaminase alone 7 6
iarrhea 2 3
ermatitis 2 0
egimen-related mortality 1 0
ll patients had grade 2 neuropathy (moderate, not interfering with
activity, and slowly resolving over several weeks to months after
all protocol therapy).
National Cancer Institute Common Toxicity Criteria, version
2—Bone Marrow Transplantation scale.
Paclitaxel, etoposide, and carboplatin.
Paclitaxel, ifosfamide, and carboplatin.Figure 1. Progression-free (PFS) and overall (OS) survival for all 33
B&MTathy characterized by generally painless hypesthesias
n a stocking-glove distribution that began within sev-
ral days to 1 week after the cycle 1 dose of paclitaxel,
eaked after the second cycle, and subsided in most
atients over several weeks to months after the last
xposure to paclitaxel. No patient experienced grade 3
r 4 nephrotoxicity in either cycle. The characteristics
or stem cell mobilization and the results of hemato-
oietic reconstitution were similar to those that we
eported previously in our study of tandem cycles of
fosfamide, carboplatin, and etoposide [9].
herapeutic Outcomes
Twelve patients (36% of all patients who were
egistered) were alive and progression free at a median
f 67 months (Figure 1). Two of these patients did not
eceive cycle 2 because of refusal or toxicities that did
ot meet off-protocol criteria. Of the other 21 pa-
ients, 1 died of therapy-related infection, and the
emaining patients relapsed and died as a result of
CT. Eight patients who achieved normalization of
erum tumor markers underwent surgical excision of
esidual masses at a median of 6 months after study
ntry. One patient had progressive disease before sur-
ery, and the other patients had surgery for residual
adiographic masses and normalized serum tumor
arkers. Of the 5 who had no pathologic evidence of
umor (4 with necrosis/ﬁbrosis and 1 with mature
eratoma), 4 (including the patient with mature tera-
oma) remain disease free after protocol therapy; all 3
atients with viable GCT (all with embryonal or yolk
ac histologic results) have died of progressive disease.
f the 24 patients whose initial prognostic category
as poor risk by the IGCCCG criteria, the outcomepatients entered onto the protocol (Kaplan-Meier analysis).
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9fter protocol therapy was similar to those of the
ntire patient population (Figure 2).
Patients were classiﬁed by the system of Beyer et
l. according to their prognostic factors just before
PSCT. This system assigns a score of 2 for -HCG
evels 1000 U/L, 2 for tumor that is absolutely
efractory to cisplatin-based therapy for relapse (pro-
ressing on therapy), and 1 each for a mediastinal
rimary tumor, a tumor that is refractory to cisplatin-
ased therapy (progressing within 4 weeks of the last
xposure), and disease progression immediately before
PSCT [13]. Of 22 patients with favorable prognostic
cores (2), 10 (45%) achieved remission and remain
rogression free, whereas only 2 (18%) of 11 with
nfavorable prognostic scores (2) remain progres-
Figure 2. A, Progression-free survival by IGCCCG risk groupion free after aPSCT (P  .05; Figure 3A). Overall d
08urvivals paralleled disease-free survivals (P  .03;
igures 1, 2B, and 3B).
ISCUSSION
The last 3 decades have witnessed the evolution of
herapy (from palliative to curative) for advanced germ
ell cancer in the vast majority of patients. Further-
ore, most of the acute toxicities of standard chemo-
herapy regimens for GCT are now readily manage-
ble with appropriate supportive care interventions,
nd the long-term toxicities of curative therapy are
odest, consisting mainly of reversible neuropathy
nd restrictive lung disease, possible accelerated car-
nosis. B, Overall survival by IGCCCG risk group at diagnosis.iovascular events, sexual dysfunction and diminished
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Bertility, and a slightly increased risk of second malig-
ancies (see review [14]). Thus, although the number
f patients for whom major improvements in therapy
re still needed is modest, they are predominantly
oung men for whom the individual effect of a cura-
ive therapy is enormous. It is unknown at present
hether improvements in aPSCT regimens will lead
o a higher fraction of cured patients or whether this
eed can be met only with the discovery of improved
gents for ﬁrst-line therapy that will be based on a
etter understanding of the molecular genetics of
hese malignancies and the individuals who develop
hem.
When our study was developed, there was general
greement that a substantial fraction of patients with
igure 3. A, Progression-free survival by Beyer risk group at the ti
f protocol entry.dvanced disease whose initial therapy failed could be a
B&MTured with aPSCT. In the United States, this was ad-
ressed with the use of tandem cycles containing carbo-
latin and etoposide with or without a third agent, gen-
rally an alkylating agent such as ifosfamide or
yclophosphamide. Data in support of the use of pacli-
axel originated from the report of Motzer et al [5].
Because there was, at the time of this study’s
nception in 1995, no widely used accepted prog-
ostic system for classifying patients in relapse or
or predicting their response to therapy, we ac-
epted a heterogeneous group of patients for treat-
ent in this study. Because the IGCCCG system
or classifying patients at the time of diagnosis has
een widely incorporated in recent protocols for
atients receiving ﬁrst-line therapy, we initially an-
protocol entry. B, Overall survival by Beyer risk group at the timeme oflyzed the entire study population and the subsets of
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9atients whose initial characteristics in the IGC-
CG fell into the poor-risk category on the basis of
erum lactate dehydrogenase, AFP, -HCG, sites of
etastasis (visceral [including bone, liver, and
rain] versus nonvisceral), and site of primary tumor
testis or retroperitoneal versus mediastinal). In our
eterogeneous study population, the initial present-
ng characteristics did not seem to predict the out-
ome of protocol therapy. This observation is not
urprising, because many other factors, especially
he rate of decline of serum tumor markers during
herapy, probably inﬂuence the outcome of ﬁrst-
ine therapy [15-18]. The use of such predictive
actors to tailor therapy is currently undergoing
valuation in a large US Intergroup study and has
een incorporated into smaller studies as well.
The prognostic system for patients in relapse was
lso derived from an international database of patients
n relapse from initial therapy who were then treated
ith aPSCT [13]. In multivariate analysis, the most
mportant prognostic factors for long-term relapse-
ree survival were progressive disease before aPSCT,
efractory or absolutely refractory disease, and an
CG level 1000 U/L. After this study was com-
leted, we assigned a prognostic score to each patient
ccording to these characteristics (mediastinal versus
onmediastinal primary tumor, progression just be-
ore aPSCT, degree of refractoriness to prior cispla-
in-based therapy, and level of -HCG). Although the
ccuracy of this system as applied to our patients may
ave been limited by missing marker data between the
ast chemotherapeutic regimen and the time of proto-
ol entry, we found a strong association between this
core and the outcome of protocol therapy, particu-
arly for patients with a high score. These patients may
e better served by participating in studies of novel
gents than by undergoing aPSCT. The Beyer prog-
ostic score should also be considered as a prestrati-
cation criterion in future phase III studies. For pa-
ients with favorable scores in this system, it may be of
reater value to explore the effect of variables such as
rug, dose, single (most common in European cen-
ers) versus tandem (used in most US centers) versus
ultiple cycles of high-dose therapy supported by
ematopoietic stem cells. An example of the latter is
he TICE regimen, consisting of 2 cycles of paclitaxel
nd ifosfamide for cytoreduction and stem cell mobi-
ization, followed by 3 cycles of high-dose carboplatin
nd etoposide, each supported by stem cells. The
ecent report of this regimen, piloted by Motzer [19]
nd updated by Kondagunta [20] showed that 75%
f patients with poor-prognosis nonseminomatous
CT (incomplete serum tumor marker response to
rst-line chemotherapy, relapsed extragonadal pri-
ary tumor, or second relapse) achieved a durable
omplete remission with chemotherapy with or with-
ut surgery. This novel regimen consists of 2 cycles of s
10aclitaxel and ifosfamide to cytoreduce the tumor and
obilize autologous peripheral blood hematopoietic
ells, followed by 3 cycles of cell-supported chemo-
herapy consisting of high-dose carboplatin and eto-
oside [19,20].
Among the most important questions that remain
o be answered in this ﬁeld is the true power of aPSCT
trategies to overcome drug resistance and, thus, cure
atients in relapse after 1 or more prior regimens.
ntil recently, the literature was composed of uncon-
rolled trials of small to moderate size featuring pa-
ients with heterogeneous characteristics who were
reated with aPSCT regimens containing 2 or 3 drugs
carboplatin and etoposide with or without cyclophos-
hamide or ifosfamide) [3]. The preliminary results of
n important European multicenter trial to compare
PSCT with standard-dose second-line therapy regi-
ens were recently published [21]. Patients in this
rial had advanced GCT in ﬁrst relapse but were not
latinum refractory (their disease had not progressed
r relapsed within 1 month of prior exposure to cis-
latin-containing chemotherapy). Those who were
andomized to standard-dose chemotherapy received
cycles of VIP or VeIP (etoposide or vinblastine with
fosfamide and cisplatin), and those who were ran-
omized to aPSCT received 3 cycles of standard-dose
hemotherapy followed by a single cycle of high-dose
arboplatin, etoposide, and cyclophosphamide with
tem cell support. The results of this trial demon-
trated no statistically signiﬁcant difference in overall
urvival between the 2 groups. The treatment mortal-
ty in the aPSCT arm was higher than that in the
tandard-dose arm, and all other outcome parameters
ere the same in the 2 groups (response rate, 1-year
vent-free survival, and overall survival). Although the
uthors reported that patients in the standard-therapy
rm did not often cross over to receive aPSCT, there
ere other potential explanations for this negative
esult. Two different reinduction regimens were avail-
ble, and only a single cycle of non–taxane-based
PSCT was administered. The dose of carboplatin
1-2.2 g/m2) is similar to that which is used in each
ycle in the ongoing US Intergroup and previous and
urrent Memorial Sloan-Kettering trials and is com-
arable to the range of carboplatin doses used in this
tudy. Furthermore, the patients enrolled in that trial
ad an unusually poor prognosis (65% of patients in
oth arms had an incomplete response to initial ther-
py) but were not stratiﬁed by IGCCCG or Beyer risk
roup.
We have shown that aPSCT using tandem cycles
ontaining high-dose paclitaxel in combination with
toposide plus carboplatin and with ifosfamide plus
arboplatin can be given safely and possesses encour-
ging activity in patients with poor-prognosis GCT.
n view of the excellent activity of paclitaxel and its
ynergy with the other agents used in this regimen, we
b
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Believe that it should undergo further testing, partic-
larly in comparison with other regimens commonly
sed in this setting, such as tandem cycles of etoposide
lus carboplatin. Many questions remain to be ad-
ressed as we attempt to identify the ideal treatment
f patients with recurrent GCT. These include the
se of other agents directed at molecular targets spe-
iﬁc to GCT and the design of disease-speciﬁc strat-
gies that do not depend on the modest dose response
chievable with currently available drugs. A better
nderstanding of the biology and unique susceptibil-
ties of these tumors will then allow investigators to
arrow the gap between cure and death in advanced
CT.
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